

TB Control and Prevention Program

Division of Disease Prevention Virginia Department of Health January 7, 2009

Topics in This Issue:

Annual Spittoon Award Winners
Targeted Testing: 2008 Exception List
FDA Warning on Fluoroquinolone Antimicrobial Drugs
2008 TB Education Materials

Annual Annual Spittoon Award Winners

The winners of the Annual Traveling Spittoon Awards were recently announced during the TB/Refugee Nurse Training that took place December 3-5 at Natural Bridge.

The Spittoon Award is given to the district in each region that achieves the highest score on several key performance factors. This year's award criteria was based on 2006 case data and included:

- Completion of therapy in less than 366 days,
- Completion of therapy in pulmonary cases on directly observed therapy (DOT), and
- Completion of therapy by contacts for latent TB infection.

In addition, complicating factors, such as HIV co-infection, homelessness, substance abuse, resistance to rifampin, or recent immigration are also considered in determining a district's performance score.

Congratulations to the following winners in each health district on their accomplishments:

Central Region:RichmondEastern Region:Virginia BeachNorthern Region:Prince William

Northwest Region: Central Shenandoah Southwest Region: Cumberland Plateau

DPP-tb appreciates the efforts of these health districts and all throughout the state who continue to work toward the eradication of tuberculosis.

Targeted Testing: Deciding Who's from a High Prevalence Country

As part of the risk assessment and target screening process, questions often arise concerning the definition of "high prevalence country" for the purposes of completing the risk assessment tool and determining who should receive a tuberculin skin test (TST). The CDC recently defined high prevalence as countries having a rate of 20 or more cases per 100,000. Individuals from countries with rates less than 20 per 100,000 should only be tested if they are symptomatic or have another individual risk factor.

2008 Exception List(i): Skin Test only if Symptomatic or an Additional Individual Risk Factor is Present

American	African	European	Asian Region	Western Pacific
Region	Region	Region		Region
Antigua	No exception	Albania	Jordan	American
Aruba	countries	Andorra	Lebanon	Samoa
Barbados		Austria	Libyan Arab	Cook Islands
Bermuda		Belgium	Jamahiriya	Australia
Canada		Czech	Oman	New Zealand
Caymen Islands		Republic	United Arab	Samoa
Chile		Cyprus	Emirates	
Costa Rica		Denmark		
Cuba		Finland		
Dominica		France		
Grenada		Germany		
Jamaica		Greece		
Montserrat		Iceland		
Netherlands		Israel		
Antilles		Ireland		
Puerto Rico		Italy		
Saint Kitts &		Luxembourg		
Nevis		Malta		
Saint Lucia		Monaco		
Trinidad &		Netherlands		
Tobago		Norway		
Turks and		San Marino		
Caicos Islands		Slovakia		
United States		Slovenia		
Virgin Islands		Sweden		
(US & BR)		Switzerland		
		United		
		Kingdom		

⁽i) Based on CDC guidance. High prevalence countries have case rates ≥ 20 per 100,000.

FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs

In July 2008, the U.S. Food and Drug Administration (FDA) issued a notification to manufacturers and released **Information for Healthcare Professionals** regarding fluoroquinolone antimicrobial drugs. The following information provides a summary of the FDA's release.

The FDA has notified manufacturers of fluoroquinolone antimicrobial drugs of the need to add a Boxed Warning in the product label concerning the increased risk of tendinitis and tendon rupture in patients taking the drugs. The FDA has also directed manufacturers of the drugs to develop a Medication Guide for patients about possible side effects. The information regarding warnings for flouroquinolones and adverse effects on tendons applies only to systemic use of the drugs (tablets, capsules and injectable forms). It does not apply to flouroquinolones for ophthalmic or otic use (eye drops and ear drops)

Fluoroquinolone are drugs approved for the treatment or prevention of certain bacterial infections. These drugs are used as second line drugs in the treatment of drug resistant/intolerant tuberculosis cases and their contacts. The medications involved in this action are:

- Cipro and generic ciprofloxacin
- Cipro XR and Proquin XR (ciprofloxacin extended release)
- Factive (gemifloxacin)
- Levaquin (levofloxacin)
- Avelox (moxifloxacin)
- Norxin (norfloxacin) and
- Floxin and generic ofloxacin



The FDA also issued **Information for Health Care Professionals** to alert them to the increased risk of tendinitis and tendon rupture in patients taking these drugs. This information states that the risk of getting tendon problems is higher if a patient is over age 60; taking steroids (corticosteroids); or a kidney, heart, or lung transplant recipient.

Patients should also avoid exercise and using the affected area at the first sign of tendon pain, swelling, or inflammation and notify their nurse case manager. Local health departments should notify VDH TB Control immediately of any patients who experience tendinitis while under treatment for a tuberculosis diagnosis.

For further information:

The full FDA Alert and Information for Healthcare Professionals on Fluoroquinolone Antimicrobial Drugs can be found at: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm

TB Education and Training Products From RTMCCs-2008 Update

There are numerous tuberculosis-specific education materials and resources to support the TB healthcare professional. The CDC-funded TB Regional Training and Medical Consultation Centers (RTMCCs) develop TB resources on a wide range of topics and in diverse formats. The following chart lists products and resources that were developed in 2008 by all of the RTMCCs; many can be downloaded directly from the RTMCC's website.

To access the complete list of TB resources developed by the RTMCCs, determine the available formats, and find links to each resource, go to: https://sntc.medicine.ufl.edu/rtmccproducts.aspx

To learn more about the RTMCCs, go to: http://www.cdc.gov/tb/rtmcc.htm

Product	Description	Produced By:
BMI Chart: Impact of Poor Nutrition on TB Relapse	Double sided flip chart	Heartland National Tuberculosis Center
Caliper for Tuberculin Skin Test Reading Country Guide – An Introduction	Information in English and Spanish is printed on caliper; contains instructions for using a caliper to measure a TST Provides an overview of the Country Guides, which help	Southeastern National Tuberculosis Center Southeastern National Tuberculosis Center
	providers work with foreign- born individuals	
Guides are currently available for the following countries: • Cambodia • Dominican Republic • Ecuador • Honduras • India • Mexico • Philippines • Somalia • Vietnam	Each country guide provides background information, epidemiology, common misperceptions and beliefs about TB and HIV/AIDS, general practices and cultural courtesies for the specific country	Southeastern National Tuberculosis Center Southeastern National Tuberculosis Center
Drug-Resistant TB: A Survival Guide for Clinicians – 2 nd Ed. Available in 2 formats: Book and CD	Contains information and tools and template for use by clinicians who participate in the management of patients with drug-resistant TB	Francis J. Curry National Tuberculosis Center

Product	Description	Produced By:
Recording of National	Special viewing steps are	Francis J. Curry
Webinar: Pediatric TB	required. Download	National Tuberculosis
	instructions at:	Center
	http://www.heartlandntbc.org/training	
D 1: CMD	/webinars/20080627/readme.pdf	TT (1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Recording of TB	Windows Media Video format;	Heartland National
Medications: Adverse	can be viewed with Windows	Tuberculosis Center
Drug Reactions with	Media Player	HEART/and
Case Studies:		NATIONAL TB CENTER
Two separate programs: Part 1 and Part 2		A PARTNERSHIP OF UT HEALTH CENTER AND TOLD
Pediatric TB for the	Includes four recorded	Southeastern National
Private Provider - CD	presentations, Q & A sessions,	Tuberculosis Center
Tilvate Hovider CD	and resource materials. Free	Tuberculosis Center
	CE and CME offered with	
	mastery of post-test and	
	completion of evaluation	
Practical Applications of	Provides an introduction to	Francis J. Curry
Genotyping in TB	genotyping, interpretation of	National Tuberculosis
Control: A National	data, the national genotyping	Center
Web-based Seminar	program and its applications	
Shelters and TB: What	Contains a viewer's guide and	Francis J. Curry
Staff need to Know,	training video about how to	National Tuberculosis
Second Edition - CD	prevent the spread of TB in	Center
	homeless shelters	
Tuberculosis Contact	For correctional liaisons who	Francis J. Curry
Investigation in Jail: A	are responsible for facilitating	National Tuberculosis
Facilitator Guide –	the training of jail and health	Center
Book/CD-Rom	department staff who conduct	
	TB contact investigation in jail	Mrs 4
		FRANCIS J. CURRY
		NATIONAL TUBERCULOSIS CENTER
Tuberculosis Program	Set of fully editable Word files	Francis J. Curry
Manual Template	that provides standardized	National Tuberculosis
	guidance to public health staff	Center
	in a low incidence region	
What Parents Need to	Provides parents with	New Jersey Medical
Know about TB	important information on TB	School Global TB
Infection in Children	infection in children; designed	Institute
	in question and answer format	MEDICAL SCHOOL GLOBAL TUBERCULOSIS
		INSTITUTE